




Percentage of Pain-Free Days (Females)




Adequate Relief by Gender (S3BA2001)



Weekly Adequate Relief (Baseline Pain)

Pain Severity ≥ 2.5




*p<0.05

—●— placebo —◆— alosetron

Pain Scale: 0=none, 1=mild, 2=moderate, 3=intense, 4=severe

12-Week Adequate Relief Rates by Baseline Pain, Urgency, and Frequency




*p < 0.05

Weekly Adequate Relief (Baseline Frequency)

Frequency ≤ 2


Frequency $> 2 - 3$



Average Number of Stools/Day during Baseline

Weekly Adequate Relief (Baseline Frequency)

Frequency > 3 - 4




Average Number of Stools/Day during Baseline

Weekly Adequate Relief (Baseline Consistency)

Consistency ≤ 3


Consistency 3 - < 4



Stool Consistency Scale: 0=none, 1=very hard, 2=hard, 3=formed, 4=loose, 5=watery

Weekly Adequate Relief (Baseline Consistency)

Consistency 4-5




Stool Consistency Scale: 0=none, 1=very hard, 2=hard, 3=formed, 4=loose, 5=watery

Control of Urgency among Severe Patients

(Urgency Control on $\geq 75\%$ of days in patients with urgency control on $\leq 30\%$ of days at baseline)

S3B30011

S3B40031




Control of Urgency among Severe Patients


(Urgency Control on $\geq 85\%$ of days in patients with urgency control on $\leq 30\%$ of days at baseline)

S3B30011

S3B40031




IBS QoL: S3BA2001, S3BA3001, S3BA3002, S3B30013 and S3B20023
Social Functioning Scale Items: Proportion of Severe Patients Improving to
None or Mild Symptoms



* $p \leq 0.001$

SA= social activities


IBS QoL: S3BA2001, S3BA3001, S3BA3002, S3B30013 and S3B20023
Activity Functioning Scale Items: Proportion of Severe Patients Improving
to None or Mild Symptoms



* $p \leq 0.05$; ** $p \leq 0.001$

W/MA = work / main activity

IBS QoL: S3BA2001, S3BA3001, S3BA3002, S3B30013 and S3B20023
Energy Scale Items: Proportion of Severe Patients Improving to None or
Mild Symptoms



* $p \leq 0.05$

Safety - 0.5mg BID Lotronex

- 11% AEs of constipation
 - Females (12/85) 14%
 - Males (15/158) 9.6%
 - Median time to onset = 8 days
- Withdrawals due to constipation
 - Females (7/85) 8%
 - Males (3/158) 2%
- Ischemic colitis - 1 subject